Qiagen N.V. (FRA:QIA)
40.34
+0.44 (1.09%)
Last updated: Jun 5, 2025
Qiagen Revenue
Qiagen had revenue of $483.46M USD in the quarter ending March 31, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to $2.00B, up 3.31% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+3.31%
P/S Ratio
4.65
Revenue / Employee
$371.18K
Employees
5,396
Market Cap
8.62B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 107.35B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Energy AG | 37.44B |
Deutsche Börse AG | 5.95B |
Qiagen News
- 2 days ago - QIAGEN expands portfolio for MRD testing in oncology with two partnerships - Seeking Alpha
- 2 days ago - QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Wallstreet:Online
- 2 days ago - QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
- 2 days ago - Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - PRNewsWire
- 13 days ago - QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Business Wire
- 21 days ago - Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential - Seeking Alpha
- 23 days ago - QIAGEN acquires AI-powered software, Genoox - Seeking Alpha
- 23 days ago - QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - Business Wire